[Proteomic analysis for the development of biopharmaceuticals].
Biopharmaceuticals represent new generation drugs that are more effective than conventional low molecular weight medicines for the treatment of cancer and other refractory diseases. In order to develop biopharmaceuticals it is critically important to explore suitable target molecules both for the diagnosis and treatment of disease. However, the choice of effective biomarker or drug target is often the most difficult part of the drug development process. Target discovery typically involves 'omics' techniques such as genomics, gene chip analysis and proteomics. Of these, proteomics is particularly important because proteins often comprise the final biomarker or drug target in the clinical sample (e.g., tissue or blood). Comprehensive proteomic analysis involves the identification of target proteins with different levels of expression between two states and is extremely useful at selecting promising candidates. Technology is then applied to further narrow down the list of relevant proteins. Here, I would like to introduce our novel procedure, termed "antibody proteomics technology", which can generate monoclonal antibody from a minute amount (i.e., nanogram level) of protein. Antibody proteomics technology can be used to easily identify suitable target molecules in order to develop effective biomarkers and drug targets.